Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.02M Buy
4,051
+173
+4% +$37.2K 0.37% 48
2026
Q1
$843K Buy
3,878
+115
+3% +$25.5K 0.35% 60
2025
Q4
$860K Buy
3,763
+62
+2% +$14.1K 0.34% 58
2025
Q3
$857K Sell
3,701
-133
-3% -$27.1K 0.35% 56
2025
Q2
$712K Buy
3,834
+510
+15% +$94.8K 0.31% 61
2025
Q1
$696K Sell
3,324
-440
-12% -$85.5K 0.33% 62
2024
Q4
$669K Buy
3,764
+148
+4% +$27.2K 0.3% 74
2024
Q3
$714K Buy
3,616
+186
+5% +$34.7K 0.31% 72
2024
Q2
$588K Hold
3,430
0.29% 74
2024
Q1
$625K Buy
3,430
+76
+2% +$13.1K 0.31% 74
2023
Q4
$520K Sell
3,354
-226
-6% -$32.9K 0.29% 80
2023
Q3
$534K Sell
3,580
-25
-0.7% -$3.67K 0.34% 72
2023
Q2
$486K Buy
3,605
+310
+9% +$45.5K 0.3% 80
2023
Q1
$525K Hold
3,295
0.35% 71
2022
Q4
$533K Buy
3,295
+509
+18% +$78K 0.4% 65
2022
Q3
$301K Hold
2,786
0.3% 81
2022
Q2
$301K Sell
2,786
-11
-0.4% -$1.68K 0.3% 81
2022
Q1
$453K Sell
2,797
-25
-0.9% -$3.63K 0.37% 62
2021
Q4
$382K Buy
2,822
+36
+1% +$4.25K 0.32% 73
2021
Q3
$301K Buy
2,786
+382
+16% +$43.6K 0.3% 81
2021
Q2
$271K Hold
2,404
0.26% 85
2021
Q1
$274K Sell
2,404
-660
-22% -$70.6K 0.27% 83
2020
Q4
$329K Buy
+3,064
New +$294K 0.31% 63

Other funds holding ABBV

Altus Wealth Group's ABBV Position: Q2 2026 in Review

Altus Wealth Group increased its AbbVie (ABBV) stake by 4.5% in Q2 2026, buying an estimated $37.2K and bringing the position to 4,051 shares worth $1.02M. The position accounts for 0.37% of the portfolio, ranked #48.

Altus Wealth Group first reported a position in ABBV in Q4 2020 and has held it in 23 quarters since. 1,951 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Altus Wealth Group held 4,051 shares of AbbVie worth $1.02M as of Q2 2026.
  • Altus Wealth Group bought 173 AbbVie shares in Q2 2026, an estimated $37.2K.
  • AbbVie made up 0.37% of Altus Wealth Group's portfolio in Q2 2026, its #48 holding.
  • Altus Wealth Group first reported a position in AbbVie in Q4 2020 and has held it in 23 quarters since.
  • 1,951 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Altus Wealth Group's 13F filing for Q2 2026, filed 17 Jul 2026.